Valeo Financial Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Valeo Financial Advisors’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,642	Closed	-$137K	–	660
2021 Q1	$137K	Hold	1,642	–	–	0.01%	534
2020 Q4	$142K	Hold	1,642	–	–	0.01%	486
2020 Q3	$115K	Hold	1,642	–	–	0.01%	442
2020 Q2	$119K	Hold	1,642	–	–	0.01%	447
2020 Q1	$84K	Hold	1,642	–	–	0.01%	463
2019 Q4	$101K	Hold	1,642	–	–	0.01%	464
2019 Q3	$70K	Hold	1,642	–	–	0.01%	511
2019 Q2	$85K	Hold	1,642	–	–	0.01%	464
2019 Q1	$91K	Hold	1,642	–	–	0.01%	429
2018 Q4	$69K	Sell	1,642 -35	-2%	-$1.83K	0.01%	443
2018 Q3	$84K	Buy	1,677 +1,613	+2,520%	+$105K	0.01%	436
2018 Q2	$4K	Hold	64	–	–	﹤0.01%	1180
2018 Q1	$4K	Hold	64	–	–	﹤0.01%	1181
2017 Q4	$4K	Sell	64 -65	-50%	-$3.67K	﹤0.01%	1055
2017 Q3	$8K	Buy	+129	New	+$7.33K	﹤0.01%	745

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UMC

United Maritime Capital New York $15.2M AUM 45.42% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Valeo Financial Advisors's BIB Position: Q2 2021 in Review

Valeo Financial Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2021, closing a stake of 1,642 shares — an estimated $137K sold.

Valeo Financial Advisors first reported a position in BIB in Q3 2017 and held it in 15 quarters. The position peaked at $142K in Q4 2020. 36 funds tracked by Wall St. Rank hold BIB as of Q2 2021.

Valeo Financial Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 1,642 ProShares Ultra NASDAQ Biotechnology shares in Q2 2021, an estimated $137K.
Valeo Financial Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2017 and held it in 15 quarters.
Valeo Financial Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $142K in Q4 2020.
36 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.